Skip to content
All articles

Retrospective cohort study of the impact of glucagon-like peptide-1 receptor agonists use on survival in head and neck squamous cell carcinoma

Dr. Nosayaba Osazuwa-Peters
Dr. Nosayaba Osazuwa-Peters

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) modulate systemic metabolism through regulating blood glucose levels and lipid metabolism. A retrospective cohort study using TriNetX Global Collaborative Network data (1990-2025) investigated whether use of GLP-1RAs with or without metformin was associated with survival outcomes of adult patients with head and neck squamous cell carcinoma (HNSCC). The primary outcome was overall survival for all HNSCC and stratified by site. The secondary outcome was overall survival among patients concurrently using GLP-1RAs and metformin. The cohort included 4532 patients (36.1% female). Across all subsites, GLP-1RA users had significantly improved overall survival compared with controls at 1 year (aHR 0.42; 95% CI 0.36-0.49) and at 5 years (0.51; 0.46-0.57). By anatomic subsite, GLP-1RA use was consistently associated with a lower hazard of mortality at 5 year (oral cavity aHR 0.60, 95% CI 0.51-0.70; oropharynx 0.51, 0.41-0.64; larynx 0.49, 0.39-0.61). Patients who used GLP-1RAs and metformin had even further improved survival benefits. The authors conclude that the findings of this cohort study suggest that there may be survival benefits associated with GLP-1RA use among patients with HNSCC across several subsites.

Original publicationjamanetwork.com
Read the publication